Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

Gaetano Pezzicoli,1,2 Elisabetta Filoni,1,2 Angela Gernone,2 Laura Cosmai,3 Mimma Rizzo,4 Camillo Porta2,5 1Department of Biomedical Sciences and Human Oncology, Post-Graduate School of Specialization in Medical Oncology, University of Bari ‘A. Moro’, Bari, Italy; 2Division of Medical Oncology, A.O....

Full description

Bibliographic Details
Main Authors: Pezzicoli G, Filoni E, Gernone A, Cosmai L, Rizzo M, Porta C
Format: Article
Language:English
Published: Dove Medical Press 2021-10-01
Series:Cancer Management and Research
Subjects:
everolimus
temsirolimus
rapa-link
anti-angiogenics
autophagy
Online Access:https://www.dovepress.com/playing-the-devils-advocate-should-we-give-a-second-chance-to-mtor-inh-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/playing-the-devils-advocate-should-we-give-a-second-chance-to-mtor-inh-peer-reviewed-fulltext-article-CMAR

Similar Items